Drugs / rabbit anti-human antithymocyte globulin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT07562568 Background | Jun 2026 → Jun 2030 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | The First Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06816134 Background | Jan 2025 → Jan 2028 expected | acute lymphoblastic leukemia, acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rabbit anti-human antithymocyte globulin | “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT06816134 ↗1“rabbit anti-human antithymocyte globulin (ATG)” NCT07562568 ↗ |
| Known as | ATG | “Cyclosporine A (CsA) + Mycophenolate mofetil dispersible tablets (MMF) + short-term low-dose methotrexate (MTX) + rabbit anti-human antithymocyte globulin (ATG)” NCT06816134 ↗1“rabbit anti-human antithymocyte globulin (ATG)” NCT07562568 ↗ |